# CMV Immunity Monitoring in Lung Transplant Recipients

> **NCT05708755** · PHASE2 · RECRUITING · sponsor: **NYU Langone Health** · enrollment: 50 (estimated)

## Conditions studied

- Lung Transplant; Complications

## Interventions

- **DEVICE:** Cytomegalovirus T Cell Immunity Panel (CMV-TCIP)
- **DIAGNOSTIC_TEST:** Donor-Derived Cell-Free DNA (dd-cfDNA) Assay
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT05708755
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-13
- **Primary completion:** 2025-09
- **Final completion:** 2026-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05708755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05708755, "CMV Immunity Monitoring in Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05708755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*